Telix collaberates with GenesisCare

Company News

by Rachael Jones

Biopharmaceutical company Telix Pharmaceuticals (ASX:TLX) has entered into a strategic collaboration agreement with GenesisCare, the largest private provider of oncology services in Australia and Europe.

Firstly, GenesisCare and Telix have established a preferred clinical provider relationship for running radiation oncology studies in Australia for the inclusion of patients into Telix’s global multi-centre trials in neuro-oncology and urologic oncology.

Secondly, they will partner to deliver compassionate use access to Telix’s glioblastoma therapy program across its patient network.

Finally, they will jointly explore the commercial potential of Telix’s products in China.

Shares in Telix Pharmaceuticals (ASX:TLX) closed 3.75 per cent lower to 77 cents. 
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.